^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

COX inhibitor

19h
New P2 trial
6d
PACES: S0820, Adenoma and Second Primary Prevention Trial (clinicaltrials.gov)
P3, N=354, Active, not recruiting, SWOG Cancer Research Network | Trial primary completion date: Feb 2027 --> Sep 2027
Trial primary completion date
|
Flynpovi (eflornithine/sulindac)
7d
Electroacupuncture Enhances Effectiveness of Omeprazole in Indomethacin-Induced Gastric Injury Mice via Nrf2 Activation and Vagus Nerve Conduction. (PubMed, Chin J Integr Med)
In mice with gastric ulcers, EA combined with Ome can better repair indomethacin-induced gastric injury via inactivation of macrophages and Nrf2-mediated antioxidant signaling pathway, which is primarily mediated by vagus nerve.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
omeprazole
8d
Hematologic responses with favorable safety in three elderly patients with polycythemia vera treated with ropeginterferon alfa-2b (PubMed, Rinsho Ketsueki)
The standard treatment is low-dose aspirin and phlebotomy, with cytoreductive therapy added for high-risk PV. All 3 patients achieved and maintained complete hematologic response with reduced JAK2 V617F allele burden. Ropeg-IFN is an effective and safe therapy for elderly patients with PV that also improves quality of life.
Journal
|
JAK2 (Janus kinase 2)
|
Besremi (ropeginterferon alfa-2b-njft) • aspirin
8d
Gastric intramural hematoma during treatment with aspirin and anagrelide in a patient with essential thrombocythemia (PubMed, Rinsho Ketsueki)
Although thrombosis prevention is crucial in ET, anagrelide is associated with a higher risk of bleeding events than other therapies. To our knowledge, this is the first reported case of gastric intramural hematoma associated with ET and anagrelide.
Journal
|
JAK2 (Janus kinase 2)
|
aspirin
8d
Supracondylar Humerus Fracture (SCHF) Post-Op Study Between Opioid and Non-Opioid Pain Management (clinicaltrials.gov)
P4, N=137, Completed, Children's Mercy Hospital Kansas City | Active, not recruiting --> Completed
Trial completion
10d
Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HR positive • HER-2 negative • HR negative • ER negative • HER-2 negative + ER positive • HER-2 negative + HR negative
|
aspirin
10d
PI20/01514: Effect of obesity due to the action of aspirin and its effectiveness in therapy for the treatment of colon cancer. (2024-515251-37-00)
P1/2, N=60, Recruiting, Fundacion Instituto De Investigacion Sanitaria Aragon | Not yet recruiting --> Recruiting
Enrollment open
|
aspirin • omeprazole
12d
IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (clinicaltrials.gov)
P3, N=137, Completed, Royal College of Surgeons, Ireland | N=300 --> 137 | Unknown status --> Completed
Trial completion • Enrollment change
|
aspirin
12d
New trial
|
aspirin
13d
Dual-Action NSAID-Gold(I) Alkynyl Hybrids for Synergistic Anti-Inflammatory and Anticancer Therapy of Colorectal Cancer. (PubMed, Inorg Chem)
Complexes based on naproxen, ibuprofen, and salicylic acid derivatives display potent antiproliferative activity against Caco-2/TC7 colon cancer cells, outperforming oxaliplatin and being comparable to auranofin, while showing markedly reduced cytotoxicity in breast cancer lines and nonmalignant cells, thus indicating promising selectivity. Additionally, complex 1 selectively inhibits the enzyme cyclooxygenase-2 (COX-2) over COX-1 and reduces IL-8 expression without affecting PTGS2 transcription, highlighting a post-transcriptional anti-inflammatory action. These results support NSAID-derived alkynyl gold(I) complexes as promising multitarget agents for colorectal cancer intervention, combining disruption and COX-2 modulation.
Journal
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
|
oxaliplatin
14d
PEAR1/EAF1 deficiency impairs aspirin responsiveness in atherosclerotic endothelium: A novel mechanism of atypical aspirin resistance. (PubMed, Microvasc Res)
The PEAR1/EAF1 interaction ameliorates aspirin resistance in atherosclerosis. This effect is associated with suppression of the endothelial NF-κB/NLRP3 inflammatory signaling pathway and altered endothelial cell fate under inflammatory stress. Targeting the PEAR1/EAF1 interaction represents a novel potential therapeutic strategy for overcoming AR.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • NLRP3 (NLR Family Pyrin Domain Containing 3) • RELA (RELA Proto-Oncogene)
|
aspirin